FDA Expands Bladder Cancer Regimen - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.

  • By

  • Kathryn Wighton

  • July 10, 2026

  • 2 min

Share

Clinical Scorecard: FDA Expands Bladder Cancer Regimen

At a Glance

CategoryDetail
ConditionMuscle-invasive bladder cancer
Key MechanismsNeoadjuvant treatment with pembrolizumab and enfortumab vedotin-ejfv
Target PopulationAdults with muscle-invasive bladder cancer who are candidates for cystectomy
Care SettingOncology clinical practice

Key Highlights

  • FDA approved pembrolizumab with enfortumab vedotin-ejfv for neoadjuvant and adjuvant therapy
  • Approval expands indication to all eligible adults, not just those ineligible for cisplatin
  • Based on KEYNOTE-B15/EV-304 trial with 808 enrolled patients
  • Median event-free survival not reached in pembrolizumab group; 48.5 months in gemcitabine plus cisplatin group
  • Safety profile consistent with prior trials in urothelial cancer

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider pembrolizumab plus enfortumab vedotin-ejfv as neoadjuvant treatment for eligible patients

    Monitoring & Follow-up

      Risks

      • Warnings for immune-mediated adverse reactions, infusion-related reactions, and embryo-fetal toxicity for pembrolizumab
      • Warnings for skin reactions, hyperglycemia, and embryo-fetal toxicity for enfortumab vedotin-ejfv

      Patient & Prescribing Data

      Adults with muscle-invasive bladder cancer candidates for cystectomy

      Combination therapy with pembrolizumab and enfortumab vedotin-ejfv shows promising efficacy

      Clinical Best Practices

      • Utilize neoadjuvant therapy in eligible patients to improve surgical outcomes
      • Monitor for adverse reactions associated with pembrolizumab and enfortumab vedotin-ejfv

      Related Resources & Content

      Original Source(s)

      FDA Expands Bladder Cancer Regimen

      • by Kathryn Wighton

      • July 10, 2026

      Related Content

      Low IMA Ligation Did Not Significantly Reduce Leaks

      A randomized trial found similar short-term morbidity and 12-month functional outcomes with both approaches, while highlighting the need to balance perfusion with a tension-free anastomosis.

      Cell Aging May Predict Future Disease

      Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

      FDA Expands Gene Therapy for Younger Patients

      Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.